Evidence map›Paper›PMID 31004274›Full record

ArticleMolecular imaging and biology2020

Molecular Imaging of a Zirconium-89 Labeled Antibody Targeting Plasmodium falciparum-Infected Human Erythrocytes.

Janie Duvenhage, Thomas Ebenhan, Seike Garny, Ignacio Hernández González, René Leyva Montaña, Roger Price, Lyn-Marie Birkholtz, Jan Rijn Zeevaart

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Development of anFrontiers in immunology · 2021
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Janie DuvenhageDepartment of Biochemistry, Genetics and Microbiology, Institute of Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Thomas EbenhanPreclinical Imaging Facility, The South African Nuclear Energy Corporation SOC Ltd (Necsa), Pelindaba, South Africa.
Seike GarnyDepartment of Biochemistry, Genetics and Microbiology, Institute of Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Ignacio Hernández GonzálezDepartment of Development, Center of Isotopes, Havana, Cuba.
René Leyva MontañaDeparment of Radiopharmacy, Center of Isotopes, Havana, Cuba.
Roger PriceDepartment of Physics, University of Western Australia, Perth, Australia.
Lyn-Marie BirkholtzDepartment of Biochemistry, Genetics and Microbiology, Institute of Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
Jan Rijn ZeevaartPreclinical Imaging Facility, The South African Nuclear Energy Corporation SOC Ltd (Necsa), Pelindaba, South Africa. janrijn.zeevaart@necsa.co.za.
South African Nuclear Energy Corporation (South Africa) · ZAUniversity of Pretoria · ZANorth-West University · ZASir Charles Gairdner Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNuclear imaging is an important preclinical research tool to study infectious diseases in vivo and could be extended to investigate complex aspects of malaria infections. As such, we report for the first time successful radiolabeling of a novel antibody specific to Plasmodium-infected erythrocytes (IIIB6), its in vitro assessment and molecular imaging in nude mice. PROCEDURES: In vitro confocal microscopy was used to determine the stage-specificity of Plasmodium-infected erythrocytes recognised by IIIB6. To enable micro-positron emission tomography (PET)/X-ray computed tomography (CT) imaging, IIIB6 was conjugated to Bz-DFO-NCS and subsequently radiolabeled with zirconium-89. Healthy nude mice were injected with [

resultsIIIB6 recognised all the relevant stages of Plasmodium falciparum-infected erythrocytes (trophozoites, schizonts and gametocytes) that are responsible for severe malaria pathology. [

conclusionIn vitro characterization of IIIB6 and pharmacokinetic characterization of [

Indexed as

AnimalsAntibodies, MonoclonalCells, CulturedErythrocytesFemaleHumansImmunoconjugatesMalaria, FalciparumMiceMice, Inbred BALB CMice, NudeMolecular ImagingPlasmodium falciparumPositron Emission Tomography Computed TomographyRadioisotopesTissue DistributionAntibodies, MonoclonalImmunoconjugatesRadioisotopesZirconiumZirconium-89[89Zr]IIIB6Micro-PET/CT imagingNimotuzumabPlasmodium falciparumZirconium-89

Identifiers

PMID31004274
OpenAlexW2935747485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.